GSK-3beta controls osteogenesis through regulating Runx2 activity. - Wikidata - awgldk - TriplyDB

GSK-3beta controls osteogenesis through regulating Runx2 activity.

GSK-3beta controls osteogenesis through regulating Runx2 activity.

http://www.wikidata.org/entity/Q33296995

about

RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads Lef1 haploinsufficient mice display a low turnover and low bone mass phenotype in a gender- and age-specific manner Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation.Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation.Novel links among Wnt and TGF-beta signaling and Runx2.Runx2 is required for early stages of endochondral bone formation but delays final stages of bone repair in Axin2-deficient mice.The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.Plant homeodomain finger protein 2 promotes bone formation by demethylating and activating Runx2 for osteoblast differentiation BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity High throughput transcriptome profiling of lithium stimulated human mesenchymal stem cells reveals priming towards osteoblastic lineage.O-GlcNAc modification of the runt-related transcription factor 2 (Runx2) links osteogenesis and nutrient metabolism in bone marrow mesenchymal stem cells.β-Catenin independent cross-control between the estradiol and Wnt pathways in osteoblasts Fibroblast growth factor 2 stimulation of osteoblast differentiation and bone formation is mediated by modulation of the Wnt signaling pathway.Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.Frontal Bone Insufficiency in Gsk3β Mutant Mice.Update on Wnt signaling in bone cell biology and bone disease.A specific role for phosphoinositide 3-kinase and AKT in osteoblasts?E3 Ubiquitin Ligase Fbw7 Negatively Regulates Osteoblast Differentiation by Targeting Runx2 for Degradation.Wnt signaling in bone development and disease: making stronger bone with Wnts Transcriptome correlation analysis identifies two unique craniosynostosis subtypes associated with IRS1 activation.Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice Wnt signaling in bone formation and its therapeutic potential for bone diseases.A novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cells.Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells Wnt signaling behaves as a "master regulator" in the osteogenic and adipogenic commitment of human amniotic fluid mesenchymal stem cells.GSK-3β function in bone regulates skeletal development, whole-body metabolism, and male life span Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor.Targeting the Wnt signaling pathway to augment bone formation.Post-translational Regulation of Runx2 in Bone and Cartilage.Environmental Factors Impacting Bone-Relevant Chemokines.Identification of Elongated Primary Cilia with Impaired Mechanotransduction in Idiopathic Scoliosis Patients.Effects of 6-Hydroxyflavone on Osteoblast Differentiation in MC3T3-E1 Cells.Wnt and the Wnt signaling pathway in bone development and disease.Control of osteogenesis by the canonical Wnt and BMP pathways in vivo: cooperation and antagonism between the canonical Wnt and BMP pathways as cells differentiate from osteochondroprogenitors to osteoblasts and osteocytes.Emerging therapeutic targets for osteoporosis treatment.Theobromine Upregulates Osteogenesis by Human Mesenchymal Stem Cells In Vitro and Accelerates Bone Development in Rats.Bone Cell Bioenergetics and Skeletal Energy Homeostasis.Covalent Modifications of RUNX Proteins: Structure Affects Function.

P2860

Q26800112-26964CCC-A840-45F7-A64B-14F1B592CECB Q28477646-CB3A5028-5600-4273-B147-09CF38668651 Q33438492-54531659-E293-4443-9627-FFE6F156F558 Q33569659-48426B30-BAAA-4E62-96F6-DC4FD0A327BB Q33627269-5F98022A-E94F-4240-8555-5F3A9A5DC308 Q33735960-81D263C8-1155-4A27-809A-5F0730638381 Q34016769-6AE7967A-F3BA-4761-B6CA-5F404A928E72 Q34243232-4651D0C9-981D-4EC1-810F-CE48E9B47824 Q34289926-2401C120-AE34-472C-8019-BC259ABB9888 Q34299031-2E55782F-1737-462D-88BB-AF93F76B734F Q34576952-28559352-5430-4A0A-8D76-4C02FC1BAD7C Q34634928-8F328710-ECDA-42C6-BE3F-41BDB8A7A563 Q34981232-9E01E57B-4B15-4793-8F5D-179CC5BEF30E Q35562548-E4F4EE5C-B321-4411-8A2D-20B72B563558 Q35673760-EF8B3BE7-2A7B-45E1-9679-1668B620F10D Q35755034-F9FFFCCD-D5B3-418D-A4F8-4E60A5936891 Q35926302-0B490F55-7DF5-4FF2-9083-BE9697DE18F0 Q36083303-3A3137A7-EA16-465C-BF26-BD370EFF8E87 Q36105778-BCD621C3-50BC-40E4-8E90-616BB7B77F0F Q36407283-CA2A8771-AFE1-4525-B2DD-D67A657AFEA8 Q36418026-357C5CC4-5202-4D8D-9B51-6A18C6F7ABF3 Q36530869-11656BEF-38DA-478A-85CE-8E812CE37E87 Q36635990-EEB339F7-3A94-4EB1-8058-D8B1D462AE90 Q36638647-4BA56829-855F-404D-BD83-21BE6FBDF7C3 Q36800940-E753AE22-2F22-4682-9771-CB4532C481BD Q36999620-7B5A1DA1-36D8-4593-8ADB-CDF2F388BC72 Q37202311-A8D65475-8D71-40EA-B447-2FE147C7E7AB Q37317729-F83F7BC2-1154-46EF-BB3A-DDA59E0386C4 Q37432036-F8DFB5EE-70A2-4AFA-9005-F05AB4132114 Q37479050-B854F611-958F-4192-A9BF-DC7655352500 Q37592911-F447C1DE-9055-4975-BE56-F5439AAFA99B Q37639340-05ED7CC2-DDAF-4453-9E19-F5A5962F64A7 Q37698831-C379F9DB-CC0E-436B-BF9A-78A542396785 Q37699828-13D96330-6CE0-4A84-856F-C8EFD404B4CF Q37724188-BEDD7D75-1126-4A7B-83FF-2BA53F4121E0 Q38038834-479DB4EC-B1BA-45E6-945A-C64E0C97090F Q38207147-682D4FCA-8775-4D7F-A41C-61FC5328C656 Q38376984-28C2AFB5-34FB-4EBC-9C98-4D745A175409 Q39137277-D3262B54-6465-40C7-89D6-46A0C10CA5D0 Q39181397-D90A164D-06B2-4B30-AA1F-BA56B9A4DC08

P2860

GSK-3beta controls osteogenesis through regulating Runx2 activity.

http://www.wikidata.org/entity/Q33296995

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@ast

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@en

type

label

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@ast

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@en

prefLabel

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@ast

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@en

P1433

Q33296995-A9C8D324-5A1D-4A48-A78A-8098C161083F

P1476

Q33296995-55168959-3986-48BF-A31B-B799B3DE4A00

P2093

Q33296995-03EF1824-4829-49DE-8BA1-80833C94C448

Q33296995-29572DBE-2664-4296-A3E9-36FDEDA95710

Q33296995-2B9A1880-3867-4AFD-B1A5-84F732E76148

Q33296995-662035B6-2321-4833-8D16-81421C33555E

Q33296995-AD0209E7-CBD2-49C1-9B75-9323236D1DFB

Q33296995-BA606DE6-326D-4C20-9659-82A490A38B61

Q33296995-CAC026FD-2CC7-44E3-927A-A9DA5684B5F2

Q33296995-D3257302-0AA6-42EE-9AC0-9BF65F166E5E

Q33296995-FB0D56EB-C4E8-4508-8D21-6E17A37263C7

P2860

Q33296995-00F9313E-601B-4439-A9D9-ED3DB58A19AC

Q33296995-01EED370-F615-4AE6-98C9-49C28422F449

Q33296995-0D66CF1A-54C3-4AC8-BC8E-A9267B6E899C

Q33296995-15BC55FF-A28E-4B9E-BB57-2BC51625E15F

Q33296995-1B8D5CC2-D855-49CE-8CF8-9445B9D82DC4

Q33296995-26625A0B-C349-43BF-BB76-B53FE0FCA3C8

Q33296995-2802A061-1E1F-45C4-896A-9A2D892CB7FB

Q33296995-29DA447E-684A-49BF-A79D-CBD303C2C4C7

Q33296995-2B1D56D1-7BFF-4561-8313-54912477672F

Q33296995-33BE5F2D-042E-43B9-8541-4545D0859A76

P304

Q33296995-AE869A93-D955-44F7-8EAF-125C56C1FC59

P31

Q33296995-1EB00038-C171-4F9B-B2E8-608C6E0B0B6D

P356

Q33296995-DE79B1F6-BCC7-4F6C-90F4-38411BF1C3C8

P407

Q33296995-5269F5E8-1799-46A2-8FCB-58F362BD14A9

P433

Q33296995-C015C57E-3547-4B6D-B644-57535D21270A

P478

Q33296995-14C5BADD-B12A-40DA-92D4-F15C898173CF

P50

Q33296995-868D2C53-5A2A-4407-8416-2BAAE0150EA4

P577

Q33296995-A2C4DA0F-83F4-4923-A271-3C859477BA9E

P5875

Q33296995-75D846E2-AD29-4DD8-B1C0-DD041252DED7

P698

Q33296995-443556D1-037F-45CA-970A-39F57234720D

P932

Q33296995-E9344A46-D501-4736-A2FF-7DA8C8A96557

P356

JOURNAL.PONE.0000837

P1433

P1476

GSK-3beta controls osteogenesis through regulating Runx2 activity.

@en

P2093

Fumitaka Kugimiya

http://www.w3.org/2001/XMLSchema#string

Hiroshi Kawaguchi

http://www.w3.org/2001/XMLSchema#string

Hirotaka Chikuda

http://www.w3.org/2001/XMLSchema#string

Kozo Nakamura

http://www.w3.org/2001/XMLSchema#string

Makoto Hirata

http://www.w3.org/2001/XMLSchema#string

Naohiro Kawamura

http://www.w3.org/2001/XMLSchema#string

Shinsuke Ohba

http://www.w3.org/2001/XMLSchema#string

Ung-il Chung

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Azuma

http://www.w3.org/2001/XMLSchema#string

P2860

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

GSK-3: tricks of the trade for a multi-tasking kinase

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

High bone density due to a mutation in LDL-receptor-related protein 5

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

Specificity and mechanism of action of some commonly used protein kinase inhibitors

P304

e837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0000837

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

James R. Woodgett

P577

2007-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6054739

http://www.w3.org/2001/XMLSchema#string

P698

17786208

http://www.w3.org/2001/XMLSchema#string

P932

1950686

http://www.w3.org/2001/XMLSchema#string